pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2016-26-6-760-765pulmo-801Research ArticleОБЗОРЫREVIEWИнгаляционный маннитол – новый муколитический препарат для лечения муковисцидозаInhaled mannitol as a new mucolytic for treatment of cystic fibrosisГориноваЮ. В.GorinovaYu. V.

119991, Москва, Ломоносовский проспект, 2, стр. 1

к. м. н., старший научный сотрудник отделения пульмонологии и аллергологии Федерального государственного автономного учреждения «Научный центр здоровья детей» Министерства здравоохранения Российской Федерации; тел.: (499)1349331

Lomonosovskiy pr. 2, build. 1, Moscow, 119991, Russia

Candidate of Medicine, Senior Researcher at Division of Pulmonology and Allergy, Federal Academic Centre of Children's Health, Healthcare Ministry of Russia; tel.: (499) 1349331

ygorinova@yandex.ruКрасовскийС. А.KrasovskiyS. A.

105077, Москва, ул. 11-я Парковая, 32, корп. 4;

105077, Москва, ул. 11-я Парковая, 32

к. м. н., старший научный сотрудник лаборатории муковисцидоза Федерального государственного бюджетного учреждения «Научноисследовательский институт пульмонологии Федерального медико-биологического агентства России»; врач-пульмонолог 2-го пульмонологического отделения Государственного бюджетного учреждения здравоохранения города Москвы «Городская клиническая больница имени Д.Д.Плетнева Департаментаздравоохранения города Москвы»; тел.: (495) 9652324

ul. Odinnadtsataya Parkovaya 32, build. 4, Moscow, 105077, Russia;

ul. Odinnadtsataya Parkovaya 32, build. 4, Moscow, 105077, Russia

Candidate of Medicine, Senior Researcher at Laboratory of Cystic Fibrosis, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; pneumologist at the 2nd Pulmonology Department, D.D.Pletnev City Clinical Hospital, Moscow Healthcare Department; Senior Researcher at Research and Clinical Division of Cystic Fibrosis, Federal Medical Genetic Academic Center, Russian Academy of Science; tel.: (495) 9652324

sa_krasovsky@mail.ruСимоноваО. И.SimonovaO. I.

119991, Москва, Ломоносовский проспект, 2, стр. 1

д. м. н., заведующая отделением пульмонологии и аллергологии Федерального государственного автономного учреждения «Научный центр здоровья детей» Министерства здравоохранения Российской Федерации; тел.: (499) 1349331

Lomonosovskiy pr. 2, build. 1, Moscow, 119991, Russia

Doctor of Medicine, Head of Department of Pulmonology and Allergology, Federal Academic Centre of Children's Health, Healthcare Ministry of Russia; tel.: (499) 1349331

oisimonova@mail.ruАмелинаЕ. Л.AmelinaE. L.

105077, Москва, ул. 11&я Парковая, 32, корп. 4

к. м. н., заведующая лабораторией муковисцидоза Федерального государственного бюджетного учреждения «Научноисследовательский институт пульмонологии Федерального медико-биологического агентства России»; тел.: (499) 7800806

ul. Odinnadtsataya Parkovaya 32, build. 4, Moscow, 105077, Russia

Candidate of Medicine, Head of Laboratory of Cystic Fibrosis, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (499) 7800806

eamelina@mail.ruФедеральное государственное автономное учреждение «Научный центр здоровья детей» Министерства здравоохранения Российской ФедерацииРоссияFederal Academic Centre of Children's Health, Healthcare Ministry of RussiaRussian FederationФедеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства России» Государственное бюджетное учреждение здравоохранения города Москвы «Городская клиническая больница имени Д.Д.Плетнева Департамента здравоохранения города Москвы»РоссияFederal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia Federal Pulmonology Research Institute, Federal Medical and Biological Agency of RussiaRussian FederationФедеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства России»РоссияFederal Pulmonology Research Institute, Federal Medical and Biological Agency of RussiaRussian Federation201628022017266760765Copyright © Горинова Ю.В., Красовский С.А., Симонова О.И., Амелина Е.Л., 20172017Горинова Ю.В., Красовский С.А., Симонова О.И., Амелина Е.Л.Gorinova Y.V., Krasovskiy S.A., Simonova O.I., Amelina E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/801

Обзор посвящен использованию современных муколитических препаратов с доказанной эффективностью при муковисцидозе. Подробно представлены результаты клинических исследований применения гипертонического раствора и маннитола у пациентов с муковисцидозом. Приводится краткая информация о проводимых в настоящее время клинических исследованиях экспериментальных муколитических препаратов.

Mucolytics with efficacy approved for cystic fibrosis (CF) have been reviewed by the authors. Currently, investigators search for new mucoactive agents to improve sputum rheology and expectoration in CF. One the promising mucolytics is inhaled dry powder mannitol which was effective and safe in several international trials. Inhaled mannitol has been implemented in clinical practice for CF treatment in some countries. Therefore, goals of new studies should be optimization the use, determination the target population and investigation of combined therapy with different mucolytics in CF.

муковисцидозмуколитические препаратыдорназа альфаингаляцииклинические исследованиягипертонический растворгиалуроновая кислотаманнитолcystic fibrosismucolytic agentsdornase alfainhalationclinical trialshypertonic saline solutionhyaluronic acidmannitolReferencesКапранов Н.И., Каширская Н.Ю. ред., Муковисцидоз. М.: МедпрактикаМ; 2014.Kapranov N.I., Kashirskaya N.Yu., eds. Cystic fibrosis. Moscow: MedpraktikaM; 2014 (in Russian).Каширская Н.Ю., Красовский С.А., Черняк А.В. и др. Динамика продолжительности жизни больных муковисцидозом, проживающих в Москве, и ее связь с получаемой терапией: ретроспективный анализ за 1993–2013 гг. Вопросы современной педиатрии. 2015; 14 (4): 503–508.Kashirskaya N.Yu., Krasovskiy S.A., Chernyak A.V. et al. Change in the life expectancy of Moscow patients with cystic fibrosis and its relationship with treatment: a retrospective analysis during 1993 – 2013. Voprosy sovremennoy pediatrii. 2015; 14 (4): 503–508 (in Russian).Красовский С.А., Черняк А.В., Каширская Н.Ю. и др. Муковисцидоз в России: создание национального регистра. Педиатрия. Журнал им. Г.Н.Сперанского. 2014; 93 (4): 44–55.Krasovskiy S.A., Chernyak A.V., Kashirskaya N.Yu. et al. Cystic fibrosis in Russia: development of the National Register. Pediatriya. Zhurnal im. G.N.Speranskogo. 2014; 93 (4): 44–55 (in Russian).Boucher RC Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Int. Med. 2007; 261: 5–16.Boucher R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Int. Med. 2007; 261: 5–16.O’Sullivan B.P., Flume P. The clinical approach to lung disease in patients with cystic fibrosis. Semin. Respir. Crit. Care Med. 2009; 30 (5): 505–513.O’Sullivan B.P., Flume P. The clinical approach to lung disease in patients with cystic fibrosis. Semin. Respir. Crit. Care Med. 2009; 30 (5): 505–513.Flume P.A., Robinson K.A., O’Sullivan B.P. et al. Cysticfibrosis pulmonary guidelines: airway clearance therapies. Respir. Care. 2009; 54: 522–537.Flume P.A., Robinson K.A., O’Sullivan B.P. et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir. Care. 2009; 54: 522–537.Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: A European consensus. J. Cyst. Fibrosis. 2005; 4: 7–26.Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: A European consensus. J. Cyst. Fibrosis. 2005; 4: 7–26.Shah P., Conway S., Scott S. et al. A casecontrolled study with Dornase Alfa to evaluate impact on disease progression over a 4 year period. J. Respiration. 2001; 68: 160–164.Shah P., Conway S., Scott S. et al. A casecontrolled study with Dornase Alfa to evaluate impact on disease progression over a 4 year period. J. Respiration. 2001; 68: 160–164.Симонова О.И., Горинова Ю.В. Сравнительные характеристики известных муколитиков в базисной терапии муковисцидоза у детей. Педиатрическая фармакология. 2014; 11 (6): 96–103.Simonova O.I., Gorinova Yu.V. A comparative characteristics of mucolytics in the basic therapy of cystic fibrosis in children. Pediatricheskaya farmakologiya. 2014; 11 (6): 96–103. (in Russian).Fushs H.J., Borowitz D.S., Christiansen D.H. et al. Effect of aerolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 1994; 331: 637–642.Fushs H.J., Borowitz D.S., Christiansen D.H. et al. Effect of aerolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 1994; 331: 637–642.Mall M., Grubb B.R., Harkema J.R. et al. Increased airway epithelial Na+ absorption produces cystic fibrosislike lung disease in mice. Nat. Med. 2004; 10: 487–493.Mall M., Grubb B.R., Harkema J.R. et al. Increased airway epithelial Na+ absorption produces cystic fibrosislike lung disease in mice. Nat. Med. 2004; 10: 487–493Robinson M., Hemming A.L., Regnis J.A. et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997; 52: 900–903.Robinson M., Hemming A.L., Regnis J.A. et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997; 52: 900–903.Donaldson S.H., Bennett W.D., Zeman K.L. et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006; 354: 241–250.Donaldson S.H., Bennett W.D., Zeman K.L. et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006; 354: 241–250.Elkins M.R., Robinson M., Rose B.R. et al. A controlled trial of longterm inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 2006; 354 (3): 229–240.Elkins M.R., Robinson M., Rose B.R. et al. A controlled trial of longterm inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 2006; 354 (3): 229–240.Wark P., McDonald V.M. Nebulised hypertonic saline for cystic fibrosis. Cochr. Database Syst. Rev. 2009; 2: CD001506.Wark P., McDonald V.M. Nebulised hypertonic saline for cystic fibrosis. Cochr. Database Syst. Rev. 2009; 2: CD001506.Rosenfeld M., Davis S., Brumback L. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: Shortterm tolerability, adherence and safety. Pediatr. Pulm. 2011; 46 (7): 666–671.Rosenfeld M., Davis S., Brumback L. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: Shortterm tolerability, adherence and safety. Pediatr. Pulm. 2011; 46 (7): 666–671.Amin R., Subbarao P., Jabar A. et al. Hypertonic saline improves the LCI in pediatric patients with CF with normal lung function. Thorax. 2010; 65 (5): 379–383.Amin R., Subbarao P., Jabar A. et al. Hypertonic saline improves the LCI in pediatric patients with CF with normal lung function. Thorax. 2010; 65 (5): 379–383.Симонова О.И., Горинова Ю.В., Бакрадзе М.Д. Эффективность ингаляций гипертонического раствора у детей с бронхитами и бронхиолитами. Вопросы современной педиатрии. 2014; 13 (4): 33–39.Simonova O.I., Gorinova Yu.V., and Bakradze M.D. Efficacy of inhaled hypertonic solution in children with bronchitis and bronchiolitis. Voprosy sovremennoy pediatrii. 2014; 13 (4): 33–39 (in Russian).Turino G.M., Cantor J.O. Hyaluronan in respiratory injury and repair. Am. J. Respir. Crit. Care Med. 2003; 167: 1169–1175.Turino G.M., Cantor J.O. Hyaluronan in respiratory injury and repair. Am. J. Respir. Crit. Care Med. 2003; 167: 1169–1175.Buonpensiero P., De Gregorio F., Sepe A. et al. Hyaluronic acid improves ‘‘pleasantness’’ and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv. Ther. 2010; 27: 870–878.Buonpensiero P., De Gregorio F., Sepe A. et al. Hyaluronic acid improves ‘‘pleasantness’’ and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv. Ther. 2010; 27: 870–878.Heijerman H., Westerman E., Conway S. et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J. Cyst. Fibros. 2009; 8 (5): 295–315.Heijerman H., Westerman E., Conway S. et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J. Cyst. Fibros. 2009; 8 (5): 295–315.Ratjen F. Restoring airway surface liquid in cystic fibrosis. N. Engl. J. Med. 2006; 354: 291–293.Ratjen F. Restoring airway surface liquid in cystic fibrosis. N. Engl. J. Med. 2006; 354: 291–293.Hurt K., Bilton D. Inhaled mannitol for the treatment of cystic fibrosis. Exp. Rev. Respir. Med. 2012; 6: 19–26.Hurt K., Bilton D. Inhaled mannitol for the treatment of cystic fibrosis. Exp. Rev. Respir. Med. 2012; 6: 19–26.Anderson S.D., Brannan J., Spring J. A new method for bronchialprovocation testing in asthmatic subjects using a dry powder of mannitol. Am. J. Respir. Crit. Care Med. 1997; 156: 758–765.Anderson S.D., Brannan J., Spring J. A new method for bronchialprovocation testing in asthmatic subjects using a dry powder of mannitol. Am. J. Respir. Crit. Care Med. 1997; 156: 758–765.Daviskas E., Anderson S.D., Brannan J.D. et al. Inhalation of drypowder mannitol increases mucociliary clearance. Eur. Respir. J. 1997; 10: 2449–2454.Daviskas E., Anderson S.D., Brannan J.D. et al. Inhalation of drypowder mannitol increases mucociliary clearance. Eur. Respir. J. 1997; 10: 2449–2454.Pettit R.S., Johnson C.E. Airwayrehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann. Pharmacother. 2011; 45: 49–59.Pettit R.S., Johnson C.E. Airwayrehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann. Pharmacother. 2011; 45: 49–59.Bilton D., Robinson P., Cooper P. et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur. Respir. J. 2011; 38: 1071–1080.Bilton D., Robinson P., Cooper P. et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur. Respir. J. 2011; 38: 1071–1080.Aitken M.L., Bellon G., De Boeck K. et al. Longterm inhaled dry powder mannitol in cystic fibrosis: in international randomized study. Am. J. Respir. Crit. Care Med. 2012: 185; 645–652.Aitken M.L., Bellon G., De Boeck K. et al. Longterm inhaled dry powder mannitol in cystic fibrosis: in international randomized study. Am. J. Respir. Crit. Care Med. 2012: 185; 645–652.Bilton D., Bellon G., Charlton B. Pooled analysis of two large randomized phase III inhaled mannitol studies in cystic fibrosis. J. Cystic. Fibros. 2013: 12; 367–376.Bilton D., Bellon G., Charlton B. Pooled analysis of two large randomized phase III inhaled mannitol studies in cystic fibrosis. J. Cystic. Fibros. 2013: 12; 367– 376.Button B.M., Finlayson F., Borg B. Clinical impact of inhaled mannitol in an adult cystic fibrosis population. J. Cyst. Fibros. 2013; 1: S98.Button B.M., Finlayson F., Borg B. Clinical impact of inhaled mannitol in an adult cystic fibrosis population. J. Cyst. Fibros. 2013; 1: S98.

The authors declare that there are no conflicts of interest present.